Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis

Abstract

RESULTSAt baseline, the median values of the symptom and sign scores were 10.0 (range 5.0-18.0) and 6.0 (range 2.0-13.0), respectively. At Week 4 of treatment with topical CsA 0.05%, the median values of the symptom and sign scores were 3.0 (range 0-14.0) and 3.0 (range 0-8.0), respectively. The reductions in the symptom and sign scores were statistically significant. The reduction in the need for corticosteroid was statistically significant by Week 12 of therapy. No significant side effects were reported.CONCLUSION Topical CsA 0.05%, which can help to reduce corticosteroid usage, is an effective and safe alternative for the treatment of resistant VKC. Further studies are needed to determine the optimal duration of therapy and possibility of recurrence.

Vernal keratoconjunctivitis

“… 24 , 25 More recent studies have shown even a dose of cyclosporine 0.05% 4 times per day may be effective in drug-resistant VKC in conjunction with topical corticosteroids. 26 …”

Stability and Safety Traits of Novel Cyclosporine A and Tacrolimus Ophthalmic Galenic Formulations Involved in Vernal Keratoconjunctivitis Treatment by a High-Resolution Mass Spectrometry Approach

“…The presence of ethanol leads to patients' discomfort at product instillation, especially critical in pediatric patients. In addition, commercial ophthalmic products containing cyclosporine A at lower concentration (e.g., 0.5 mg/mL, Restasis ® ), are of dubious efficacy in the treatment of VKC [18] and they are highly expensive (e.g., cyclosporine 1.0 mg/mL, Ikervis ® ). In some cases, these preparations are not registered for the treatment of VKC or they are recognized as VKC orphan drug (e.g., cyclosporine 1.0 mg/mL, Verkazia ® ) [19,20], but still not commercially available or highly expensive.…”

Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children

“…[3] Superior tarsal and limbal papillae, conjunctival hyperemia, and corneal involvement in the form of punctate epithelial keratitis, epithelial macroerosions, shield ulcers, plaque formation, and corneal neovascularization are also observed. [4] VKC can be described as IgE and T-cell mediated ocular allergic reaction with varied etiological factors comprising environmental allergens, climate, and genetic predisposition. [5] Mast cells, eosinophils, and their mediators play a major role in the clinical manifestation of the disease.…”